Alivus Life Sciences Limited
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib… Read more
Alivus Life Sciences Limited (ALIVUS) - Total Liabilities
Latest total liabilities as of September 2025: ₹6.23 Billion INR
Based on the latest financial reports, Alivus Life Sciences Limited (ALIVUS) has total liabilities worth ₹6.23 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Alivus Life Sciences Limited - Total Liabilities Trend (2021–2025)
This chart illustrates how Alivus Life Sciences Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Alivus Life Sciences Limited Competitors by Total Liabilities
The table below lists competitors of Alivus Life Sciences Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Blend Labs Inc
NYSE:BLND
|
USA | $47.25 Million |
|
AXTRART_AXTRA FUTURE CITY
BK:AXTRART
|
Thailand | ฿3.58 Billion |
|
Revance Therapeutics, Inc.
NASDAQ:RVNC
|
USA | $624.59 Million |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥630.58 Million |
|
Amorepacific Group
KO:002795
|
Korea | ₩1.39 Trillion |
|
Betagro Public Company Limited
F:J74
|
Germany | €37.92 Billion |
|
Alligo AB Series B
ST:ALLIGO-B
|
Sweden | Skr5.95 Billion |
|
Hangzhou Huaxing Chuangye Communication Technology Co Ltd
SHE:300025
|
China | CN¥357.87 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Alivus Life Sciences Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alivus Life Sciences Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alivus Life Sciences Limited (2021–2025)
The table below shows the annual total liabilities of Alivus Life Sciences Limited from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹5.94 Billion | +14.67% |
| 2024-03-31 | ₹5.18 Billion | -8.13% |
| 2023-03-31 | ₹5.64 Billion | +35.34% |
| 2022-03-31 | ₹4.17 Billion | -66.51% |
| 2021-03-31 | ₹12.44 Billion | -- |